Denali Therapeutics Inc. (DNLI): Price and Financial Metrics


Denali Therapeutics Inc. (DNLI)

Today's Latest Price: $28.82 USD

0.41 (1.44%)

Updated Jun 3 4:00pm

Add DNLI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DNLI Stock Summary

  • With a price/sales ratio of 115.08, Denali Therapeutics Inc has a higher such ratio than 97.74% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Denali Therapeutics Inc is reporting a growth rate of 318.73%; that's higher than 95.81% of US stocks.
  • As for revenue growth, note that DNLI's revenue has grown -80.35% over the past 12 months; that beats the revenue growth of just 1.47% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Denali Therapeutics Inc, a group of peers worth examining would be PRQR, FATE, PRNB, ASMB, and NKTR.
  • Visit DNLI's SEC page to see the company's official filings. To visit the company's web site, go to www.denalitherapeutics.com.
DNLI Daily Price Range
DNLI 52-Week Price Range

DNLI Stock Price Chart More Charts


DNLI Price/Volume Stats

Current price $28.82 52-week high $30.41
Prev. close $28.41 52-week low $12.39
Day low $28.34 Volume 472,702
Day high $29.39 Avg. volume 614,638
50-day MA $22.22 Dividend yield N/A
200-day MA $19.49 Market Cap 3.04B

Denali Therapeutics Inc. (DNLI) Company Bio


Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.


DNLI Latest News Stream


Event/TimeNews Detail
Loading, please wait...

DNLI Latest Social Stream


Loading social stream, please wait...

View Full DNLI Social Stream

Latest DNLI News From Around the Web

Below are the latest news stories about Denali Therapeutics Inc that investors may wish to consider to help them evaluate DNLI as an investment opportunity.

Venture Funding of Drug Startups Down, But Not Out

Fourteen biotechs have gone public in 2020, just three fewer than for the same period last year Continue reading...

Yahoo | May 28, 2020

Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity

Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.

Yahoo | May 28, 2020

Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine

Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with.

Yahoo | May 27, 2020

What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock

Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research | May 21, 2020

Analyst Estimates: Here's What Brokers Think Of Denali Therapeutics Inc. (NASDAQ:DNLI) After Its First-Quarter Report

Investors in Denali Therapeutics Inc. (NASDAQ:DNLI) had a good week, as its shares rose 9.6% to close at US$23.89...

Yahoo | May 10, 2020

Read More 'DNLI' Stories Here

DNLI Price Returns

1-mo 18.16%
3-mo 58.53%
6-mo 57.83%
1-year 51.45%
3-year N/A
5-year N/A
YTD 65.44%
2019 -15.68%
2018 32.10%
2017 N/A
2016 N/A
2015 N/A

Continue Researching DNLI

Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:

Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8272 seconds.